Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzupacap Sarotalocan (AU-011) in Bladder Cancer
NCT05483868Phase 1Active, not recruiting
- Sponsor
- Aura Biosciences, Inc.
- Start
- Sep 2022
- Primary completion
- Mar 2027
- Modality
- Nanoparticles, Recombinant Proteins and Enzymes, Peptide-Drug Conjugates
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of belzupacap sarotalocan in non-muscle-invasive bladder cancer (NMIBC) (10 arms), sponsored by Aura Biosciences, Inc. Primary endpoint: Incidences of SAEs and DLTs at 12 months. Started Sep 2022; status: active, not recruiting.
02
Drugs
belzupacap sarotalocan
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05483868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05483868.